About BigHat Biosciences
BigHat Biosciences designs antibody drugs with AI and an automated laboratory. Its Milliner platform produces and tests thousands of molecules each week, then uses the results to improve new designs.
The San Mateo company is testing BHB810 in a Phase 1 cancer trial and has other owned and partnered programs. BigHat has more than 85 employees and has raised $223 million. Peyton Greenside is its co-founder and chief executive officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | Oct 26, 2026 | $75,141,086of $79.9M target | 29 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Jun 30, 2022 | Oct 3, 2022amended Apr 28, 2025 | $124,105,981fully sold | 40 | $3.1M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jan 28, 2021 | Feb 12, 2021 | $18,834,498of $18.9M target | 6 | $3.1M | EquityRule 506(b) | Form D ↗ |
| Oct 22, 2019 | Dec 19, 2019 | $5,302,511fully sold | 12 | $441K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $223,384,076 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by BigHat Biosciences
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Sep 24, 2026 | Series C | $75M | DFJ Growth and Premji Invest (co-leads), Catalio Capital Management, LG Technology Ventures, Sigmas Group, 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz, Discovery Ventures, GRIDS Capital, Intermountain Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund, Quadrille Capital, Section 32 | bighatbio.com ↗ |
| Jul 20, 2022 | Series B | $75M | Section 32 (lead), Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC and AME Cloud Ventures; extended in 2025 by $44M, led by pharmaceutical and strategic investors | bighatbio.com ↗ Endpoints News (extension) ↗ |
| Feb 10, 2021 | Series A | $19M | Andreessen Horowitz (lead), 8VC, AME Cloud Ventures, Innovation Endeavors | bighatbio.com ↗ |
| Oct 22, 2019 | Seed | $5M | 8VC (lead), AME Cloud Ventures, Innovation Endeavors | bighatbio.com ↗ |
Why Investors Backed BigHat Biosciences
Investors backed BigHat because antibody design produces both a molecular search problem and a laboratory bottleneck. BigHat connects AI models to an automated lab that can make and test thousands of molecules each week. The company now has a drug in a Phase 1 trial and collaborations with major pharmaceutical and technology companies. Its platform can support BigHat's own drugs, partner programs and biological data generation.
The problem it targets
An antibody must bind the right target and still remain stable, manufacturable and safe. Improving one property can weaken another. Traditional design and laboratory cycles can take weeks or months, so programs may spend years moving from an early binder to a clinical candidate.
What the product does
BigHat's Milliner platform joins computational design, automated experiments and a shared data system. One workcell can produce and characterize more than 2,000 molecules each week across over 20 assays. Its models use those results to propose the next designs. BigHat applies the system to its own drug pipeline and to projects for pharmaceutical and AI partners.
Progress so far
BigHat dosed the first patient in a Phase 1 trial of BHB810 in September 2026. The company also says it completed three Merck projects, triggering an undisclosed milestone payment. Its partners have included Amgen, Merck, Johnson & Johnson, AbbVie and Lilly. A 2026 Anthropic project made and tested more than 1,000 antibody variants in about 10 weeks.
Who backs it
DFJ Growth and Premji Invest co-led the $75 million Series C. Earlier lead investors were Section 32, Andreessen Horowitz and 8VC. Strategic and life-sciences investors include Amgen Ventures, Bristol Myers Squibb, Eli Lilly and Company, Merck Global Health Innovation Fund and LG Technology Ventures.
How the market is moving
Pharmaceutical companies and AI developers are testing systems that combine models with experimental data. BigHat announced programs with Lilly and Anthropic in 2026. Its platform also produced candidates through projects with Merck and Johnson & Johnson. These relationships create demand for both drug-design work and the biological data used to improve models.
We wrote this summary from public statements by BigHat Biosciences and its investors. It is not investment advice.
BigHat Biosciences in the News
Leadership Team
Executive officers and directors listed on BigHat Biosciences's Form D filed Oct 26, 2026.
Earlier filings also listed Steve Kafka (director, last listed Apr 2025), Mark DePristo (chief executive officer and director, last listed Feb 2021) and Theresa Tribble (promoter, last listed Dec 2019).
Sources
- SECBigHat Biosciences, Inc. Form D, filed Oct 3, 2022
- SECBigHat Biosciences, Inc. filing history
- CompanyBigHat team, board and company figures
- CompanyMilliner platform
- CompanyBigHat therapeutics pipeline
- CompanyBigHat partnering model
- CompanyFirst BHB810 patient announcement
- CompanyCompleted Merck projects
- CompanyBigHat and Anthropic antibody project